About Psoriasis Cure Now

Psoriasis Cure Now (PCN) launched in 2005 with a mission to increase research funding for psoriasis and psoriatic arthritis, to educate opinion leaders and the general public about the seriousness of psoriatic disease, and to inspire and support patients and their loved ones to live their best lives despite psoriasis. Founded and run by a psoriasis patient, Psoriasis Cure Now has been aided by the hard work and financial support of hundreds of volunteers across the United States. We are a 501(c)(3) nonprofit organization.

Focused primarily on those with moderate to severe psoriasis and/or psoriatic arthritis, PCN leverages its ability to target, nimbly, areas where the psoriasis community has unmet needs. Our scrappy, unconventional vision of patient advocacy makes us willing to shake up the status quo when the status quo is not adequately serving psoriasis patients. [Learn more about our story.]

Prior to launching Psoriasis Cure Now, its founder and president, Michael Paranzino, worked at the intersection of policy, politics, and communications; as Chief of Staff and Legislative Director to a Member of Congress, as a lobbyist for the US solar energy industry, and as a communications consultant and policy advocate. He has also practiced law; worked on political campaigns; and been interviewed hundreds of times for print, radio and television. He holds degrees from Yale University and the NYU School of Law. Five members of his extended family also have psoriasis, giving him, as he puts it, “plenty of skin in the game” – and the motivation to seek swift progress for the psoriasis community. Reach him directly at: michaelp@psoriasiscurenow.org.

If you would like to assist us, be it once a year or more frequently, we would love your help. Sign up on our Volunteer page and we will find a way to leverage your talents and passion to advance the mission we share.

Volunteer with Us

The Latest Psoriasis News

Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials
Experimental psoriatic arthritis treatment filgotinib shows strong response in clinical trials

Gilead Sciences and Galapagos jointly announced results from Phase Two (mid-stage) clinical trials for their JAK1 inhibitor filgotinib for psoriatic arthritis. The companies are jointly developing the investigational treatment. JAK inhibitors, taken as pills, are receiving much attention for their ability to help people with rheumatoid arthritis (RA), psoriatic arthritis, Continue Reading…

Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis
Taltz challenges Humira in head to head clinical trial treating psoriatic arthritis

Eli Lilly and Company shared new data from its 52-week, head-to-head biologic clinical trial pitting its Taltz (ixekizumab) against AbbVie’s longtime blockbuster Humira (adalimumab) in patients with psoriatic arthritis who had not yet tried a biologic. Here’s the bottom line for those of you who just want the answers without Continue Reading…

Tremfya approval in U.S. for psoriatic arthritis looks likely
Tremfya approval in U.S. for psoriatic arthritis looks likely

Tremfya (guselkumab), is approved by the U.S. Food and Drug Administration (FDA) and regulators elsewhere for the treatment of adults with moderate to severe plaque psoriasis. It is an IL-23 inhibitor that is very successful at improving skin psoriasis. It was approved in Europe in 2019 for active psoriatic arthritis, Continue Reading…